NCT07291232
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoints: details revised at 1 of 15 entries Show 4 more changesShow less
- Eligibility criteria expanded, about 5 words
- Enrollment closed, study ongoing
- Primary and study completion dates: Mar 2027 to Apr 2027
- Site details revised at 2 of 2 sites
- Notable Enrollment increased: 48 → 80 participants
- Primary and study completion pushed from Oct 2026 to Mar 2027
- Trial arms changed: 4 → 8
- Study sites revised (2)
- Minor Study sites: 1 to 2v3
- Notable Enrollment target: 96 to 48
- Study arms: 6 to 4
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks.
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks.
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks.
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks.
Drugs: ABBV-295, Placebo
Sites
2 sites in 1 country